The pathways controlling the maintenance and loss of pluripotency in cells of the early embryo regulate the formation of the tissues that will support development. Several transcription factors have been identified as being integral to the establishment and/or maintenance of pluripotency, coordinately regulating the expression of genes within pluripotent cells and acting as gene targets of these same processes. Recent advances in understanding the transcriptional regulation of these factors have revealed differences in the transcriptional complexes present within sub-populations of the pluripotent lineage and in the mechanisms regulating the loss of pluripotency on differentiation.
Synergistic activation of the fibroblast growth factor 4 enhancer by Sox2 and Oct-3 depends on protein-protein interactions facilitated by a specific spatial arrangement of factor binding sites.
Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4
Comparative expression of the mouse Sox1, Sox2 and Sox3 genes from pre-gastrulation to early somite stages
Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells
Loss of orphan receptor germ cell nuclear factor function results in ectopic development of the tail bud and a novel posterior truncation
Phenotypic complementation establishes requirements for specific POU domain and generic transactivation function of Oct-3/4 in embryonic stem cells.
Crystal structure of a POU/HMG/DNA ternary complex suggests differential assembly of Oct4 and Sox2 on two enhancers
Oct-4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells
Identification, cloning and expression analysis of the pluripotency promoting Nanog genes in mouse and human
Conserved POU binding DNA sites in the Sox2 upstream enhancer regulate gene expression in embryonic and neural stem cells.
The stem cell pluripotency factor NANOG activates transcription with two unusually potent subdomains at its C terminus.
Phenotypic analyses of mouse embryos with ubiquitous expression of Oct4: effects on mid-hindbrain patterning and gene expression
Cdx2 is required for correct cell fate specification and differentiation of trophectoderm in the mouse blastocyst
Orphan nuclear receptor LRH-1 is required to maintain Oct4 expression at the epiblast stage of embryonic development
Oct-3/4 maintains the proliferative embryonic stem cell state via specific binding to a variant octamer sequence in the regulatory region of the UTF1 locus
Downregulation of NANOG induces differentiation of human embryonic stem cells to extraembryonic lineages
Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells
Characterization of putative cis-regulatory elements that control the transcriptional activity of the human Oct4 promoter
Orphan nuclear receptor GCNF is required for the repression of pluripotency genes during retinoic acid-induced embryonic stem cell differentiation
Phosphorylation of the hinge domain of the nuclear hormone receptor LRH-1 stimulates transactivation
Differentiation of mouse embryonic stem cells after RNA interference-mediated silencing of OCT4 and Nanog
Expression of mouse liver receptor homologue 1 in embryonic stem cells is directed by a novel promoter
Overexpression of NANOG in human ES cells enables feeder-free growth while inducing primitive ectoderm features
Characterization and genetic manipulation of human umbilical cord vein mesenchymal stem cells: potential application in cell-based gene therapy
The relationship between pluripotency and mitochondrial DNA proliferation during early embryo development and embryonic stem cell differentiation.
Tracing the derivation of embryonic stem cells from the inner cell mass by single-cell RNA-Seq analysis.
CREs: Gene & Cell Therapy
Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.